Equities

Exact Sciences Corp

Exact Sciences Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)53.07
  • Today's Change0.37 / 0.70%
  • Shares traded140.00
  • 1 Year change-18.53%
  • Beta1.2333
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7786321,030
Total Receivables, Net204158217
Total Inventory127118105
Prepaid expenses867474
Other current assets, total------
Total current assets1,1949821,426
Property, plant & equipment, net853862773
Goodwill, net2,3672,3462,335
Intangibles, net1,8901,9562,094
Long term investments------
Note receivable - long term------
Other long term assets1628056
Total assets6,4716,2276,685
LIABILITIES
Accounts payable797568
Accrued expenses371328418
Notes payable/short-term debt000
Current portion long-term debt/capital leases623.206.20
Other current liabilities, total2.927.0525
Total current liabilities515413517
Total long term debt2,3222,2442,193
Total debt2,3842,2472,199
Deferred income tax------
Minority interest------
Other liabilities, total490527587
Total liabilities3,3263,1843,297
SHAREHOLDERS EQUITY
Common stock1.821.781.74
Additional paid-in capital6,6116,3126,029
Retained earnings (accumulated deficit)(3469)(3265)(2642)
Treasury stock - common------
Unrealized gain (loss)0.05(5.29)(1.47)
Other equity, total1.370.050.02
Total equity3,1453,0433,388
Total liabilities & shareholders' equity6,4716,2276,685
Total common shares outstanding181178174
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.